JPRN-UMIN000005697Completed未知
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma - Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular Carcinoma
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Chiba University Hospital
- Enrollment
- 42
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients with a history of malignancy. 2) Corresponding to the sever heart disease. 3) Active clinically-serious infections. 4) History of HIV infection. 5) Hemodialysis. 6) Clinical or radiological evidence of CNS metastases. 7) Uncontrollable massive ascites, pleural effusion. 8) Clinically-significant gastrointestinal bleeding within 4 weeks prior to study entry. 9) Severe allergy for fluoropyrimidines. 10) HBV-DNA positive and not being treated with nucleotide analogues. 11) Anticoagulant therapy with warfarin potassium. 12) During treatment with Tegafur gimeracil oteracil potassium, or within 7 days after discontinuation. 13) Use Sho-saiko-to. 14) Use oral phenytoin. 15) Severe thyroid disease.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43
Active, not recruiting
Not Applicable
A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer - NDEUCTR2006-003752-38-ITOSPEDALE ONCOLOGICO DI BARI
Completed
Phase 1
Phase I study of a combination of capecitabine plus CPT-11 (CC therapy) in patients with metastatic colon cancer refractory to oxaliplatin containing chemotherapyColorectal cancerJPRN-UMIN000003176Osaka Medical Center for Cancer and Cardiovascular Diseases24
Completed
Phase 1
Capecitabine and erlotinib in advanced lung cancerCancerISRCTN18199864Royal Marsden NHS Foundation Trust40
Active, not recruiting
Not Applicable
Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinomfortgeschrittenes kolorektalen Karzinom mit inoperablen MetastasenMedDRA version: 9.1Level: LLTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2007-000233-18-DEniversität zu Köln